Drug Design, Development and Therapy (Jul 2023)
Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases
Abstract
Junlan Tan,1,2 Jian Yi,2,3 Xianya Cao,1,2 Feiying Wang,2,4 Silin Xie,2,4 Aiguo Dai2,4,5 1School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People’s Republic of China; 2Hunan Provincial Key Laboratory of Vascular Biology and Translational Medicine, Changsha, Hunan, 410208, People’s Republic of China; 3The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410021, People’s Republic of China; 4Department of Respiratory Diseases, School of Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People’s Republic of China; 5Department of Respiratory Medicine, the First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410021, People’s Republic of ChinaCorrespondence: Aiguo Dai, Department of Respiratory Diseases, School of Medicine, Hunan University of Chinese Medicine, 300 Xueshi Road, Hanpu Science and Education District, Changsha, Hunan, 410208, People’s Republic of China, Tel +86-731-88458128, Fax +86-731-88458111, Email [email protected]: Respiratory diseases are an emerging public health concern, that pose a risk to the global community. There, it is essential to establish effective treatments to reduce the global burden of respiratory diseases. Astragaloside IV (AS-IV) is a natural saponin isolated from Radix astragali (Huangqi in Chinese) used for thousands of years in Chinese medicine. This compound has become increasingly popular due to its potential anti-inflammatory, antioxidant, and anticancer properties. In the last decade, accumulated evidence has indicated the AS-IV protective effect against respiratory diseases. This article presents a current understanding of AS-IV roles and mechanisms in combatting respiratory diseases. The ability of the agent to suppress oxidative stress, cell proliferation, and epithelial-mesenchymal transition (EMT), to attenuate inflammatory responses, and modulate programmed cell death (PCD) will be discussed. This review highlights the current challenges in respiratory diseases and recommendations to improve disease management.Keywords: astragaloside IV, Radix astragali, respiratory diseases, oxidative stress, inflammatory responses
